Navigation Links
Improving Trial Design and Predictability in Rheumatoid Arthritis With Time Response Modeling, New Webinar July 23rd Hosted by Xtalks
Date:7/15/2014

Toronto, Canada (PRWEB) July 15, 2014

Given the high medical need in this category, there has been increasing interest in recent years on the part of biopharma in developing new, more effective compounds including biologics and biosimilars. With competition rising, it is critical to more efficiently design your clinical trials so as to accelerate cycle times and speed your products to patients in need.

Well designed time response models can be valuable tools in achieving these objectives. These models have been shown to be predictive of trial outcomes and can also be used to:

  •     Help design clinical trials
  •     Compare a new drug to existing therapies
  •     Examine the effects of time and endpoints on power and sample size
  •     Support endpoint selection

The webinar is intended to help drug developers:

  •     Optimize trial designs
  •     Review innovative trial design features and operating characteristics such as adaptive designs
  •     Investigate novel analysis methodologies to better achieve objectives
  •     Improve the probability of more efficiently and successfully developing new RA treatments

Join presenters from Quintiles, Dr. Russell Reeve, PhD, Senior Biostatistics Director, Center for Statistics in Drug Development, and Dr. Niti Goel, Senior Medical Director & Head, Rheumatology Center of Excellence, for an information session that will include a Q&A with the audience.

For more information or to register for this webinar, visit: Time Response Modeling in Rheumatoid Arthritis and Other Autoimmune Indications

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com.
For information about hosting a webinar, visit http://xtalks.com/sponsorship.ashx.

Contact:
Michelle Tran
Tel: +1 (416) 977-6555 ext 352
Email: mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2014/07/prweb12012695.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness"
2. IVF improving but fertility treatments keep multiple births high
3. Nanotubes can solder themselves, markedly improving device performance
4. FDA Guidance on Risk-based Monitoring While Improving Data Quality, New Life Science Webinar Hosted by Xtalks
5. Case Report Suggests Microbiome Therapeutics NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control
6. SASB Releases Provisional Sustainability Accounting Standards for Health Care Industry, A Key Milestone in Improving Disclosure of Material Non-Financial Information
7. Patheon to Host Webinar on “Accelerating the Drug Development Trajectory by Improving Solubility of New Compounds”
8. Consumer Survey Indicates Mouth Guards Worsen TMJ Symptoms As Often As Significantly Improving Them – Holistic Technologies
9. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
10. Cord Blood America President Says Company Must Continue Improving Financial Results
11. Clearing the air: PNNL technology wins award for improving submarine air quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total ... successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, ... The procedure was an anterior cervical discectomy and fusion on a 42 year ...
(Date:1/18/2017)... ... , ... Researchers from a new study are stating that if levels of the ... treatment, this indicates there is still remaining prostate cancer cells that are more likely to ... has always been an indicator of whether a man’s prostate cancer is growing or ...
(Date:1/18/2017)... ... January 18, 2017 , ... Thirty-six startup companies in University City ... Pennsylvania Department of Community and Economic Development in 2016 as part of the Keystone ... University City Keystone Innovation Zone and represent the highest number of awards to the ...
Breaking Biology Technology:
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... biometric sensor technology, today announced the launch of ... sensor systems, the highly-accurate biometric sensor modules that ... biometric technology, experience and expertise. The two new ... designed specifically for hearables, and Benchmark BW2.0, a ...
(Date:12/20/2016)... The rising popularity of mobility services ... stoking significant interest in keyless access systems. Following ... energy (BLE), biometrics and near-field communication (NFC) are ... wireless technologies in the automotive industry. This evolution ... systems opens the market to specialist companies such ...
(Date:12/16/2016)... Research and Markets has announced the addition of the "Biometric ... to their offering. ... The biometric vehicle access system market, in terms of value, ... to 2021. The market is estimated to be USD 442.7 Million ... The growth of the biometric vehicle access system market is fueled ...
Breaking Biology News(10 mins):